U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18FN3O4
Molecular Weight 371.3623
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GSK-364735

SMILES

CN1C(=O)C(C(=O)NCCO)=C(O)C2=NC=C(CC3=CC=C(F)C=C3)C=C12

InChI

InChIKey=QWLNINWUBHHOLU-UHFFFAOYSA-N
InChI=1S/C19H18FN3O4/c1-23-14-9-12(8-11-2-4-13(20)5-3-11)10-22-16(14)17(25)15(19(23)27)18(26)21-6-7-24/h2-5,9-10,24-25H,6-8H2,1H3,(H,21,26)

HIDE SMILES / InChI
GlaxoSmithKline was developing GSK-364735 as a human immunodeficiency virus (HIV) integrase inhibitor. The inhibition of viral DNA integration takes place by interacting at the two-metal binding site within the catalytic center of HIV integrase. GSK-364735 was successfully studied at Phase II in HIV-infected patients; however, adverse liver effects of GSK364735 were recently observed in a long-term preclinical safety study in the monkey and preclude further development of the compound.

Approval Year

PubMed

PubMed

TitleDatePubMed
Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and repeated administration in healthy adult subjects.
2007 Dec
Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion.
2007 Nov
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
2008 Mar
Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
2009 Feb 24
Patents

Sample Use Guides

In part A, three alternating cohorts of 10 subjects (8 receiving the active drug and 2 receiving a placebo) received single doses of 50 to 400 mg while fasting or 200 mg and 400 mg coadministered with food. In part B, five cohorts received repeated doses of 100 to 600 mg daily coadministered with food for 8 days.
Route of Administration: Oral
Name Type Language
GSK-364735
Common Name English
GSK364735
Code English
NAPHTHYRIDINONE
Systematic Name English
1,5-NAPHTHYRIDINE-3-CARBOXAMIDE, 7-((4-FLUOROPHENYL)METHYL)-1,2-DIHYDRO-4-HYDROXY-N-(2-HYDROXYETHYL)-1-METHYL-2-OXO-
Systematic Name English
7-((4-FLUOROPHENYL)METHYL)-4-HYDROXY-N-(2-HYDROXYETHYL)-1-METHYL-2-OXO-1,5-NAPHTHYRIDINE-3-CARBOXAMIDE
Systematic Name English
S/GSK-364735
Code English
S/GSK 364735
Code English
S-364735
Code English
Code System Code Type Description
PUBCHEM
54718859
Created by admin on Sat Dec 16 10:41:48 GMT 2023 , Edited by admin on Sat Dec 16 10:41:48 GMT 2023
PRIMARY
DRUG BANK
DB13119
Created by admin on Sat Dec 16 10:41:48 GMT 2023 , Edited by admin on Sat Dec 16 10:41:48 GMT 2023
PRIMARY
FDA UNII
SXN0KXT60S
Created by admin on Sat Dec 16 10:41:48 GMT 2023 , Edited by admin on Sat Dec 16 10:41:48 GMT 2023
PRIMARY
CAS
863434-13-3
Created by admin on Sat Dec 16 10:41:48 GMT 2023 , Edited by admin on Sat Dec 16 10:41:48 GMT 2023
PRIMARY